Photo: Tassii/Getty Images

照片：塔西/盖蒂图片社

UK-based healthcare technology company Huma announced it secured more than $80 million in a Series D funding round, bringing its total raise to over $300 million.

总部位于英国的医疗保健技术公司Huma宣布，它在D轮融资中获得了8000多万美元，使其总筹资额达到3亿多美元。

New and existing investors, including AstraZeneca, Leaps by Bayer, Hat Technology Fund 4 by HAT SGR, and HV Fund by Hitachi Ventures, participated in the round.

新的和现有的投资者，包括阿斯利康（AstraZeneca）、拜耳（Leaps by Bayer）、Hat SGR的Hat Technology Fund 4和日立风险投资（Hitachi Ventures）的HV Fund，都参加了这轮投资。

The company, which creates applications that integrate patient data from hospital databases, mobile devices, and wearables for providers, also announced the launch of its new product, Huma Cloud Platform.

该公司还宣布推出其新产品Huma云平台，该公司创建的应用程序可集成来自医院数据库、移动设备和可穿戴设备的患者数据。

Huma Cloud is a no-code platform that allows developers to create disease management tools using a library of pre-built modules and device connectivity capabilities. The cloud-agnostic framework also offers APIs and integration capabilities and can host and deploy predictive and diagnostic AI algorithms.   .

Huma Cloud是一个无代码平台，允许开发人员使用预先构建的模块库和设备连接功能创建疾病管理工具。云不可知框架还提供API和集成功能，可以承载和部署预测和诊断AI算法。。

'We have known Huma for several years and we've been impressed by their remarkable progress. We have seen this first-hand. They have demonstrated strong growth and excellent metrics,' Dr. Juergen Eckhardt, EVP, head of Leaps by Bayer and pharmaceuticals business, development and licensing, said in a statement. .

“我们认识人类已经好几年了，他们取得的显著进步给我们留下了深刻印象。我们亲眼目睹了这一点。拜耳Leaps和制药业务、开发和许可主管、执行副总裁尤尔根·埃克哈特（JuergenEckhardt）博士在一份声明中说，他们表现出强劲的增长和出色的指标。。

'With their next-generation AI capabilities and Huma Cloud platform, Huma can partner with pharma companies to deliver efficient digital health solutions to patients focused on predictive and proactive care.'

“凭借其下一代人工智能功能和Huma云平台，Huma可以与制药公司合作，为专注于预测性和前瞻性护理的患者提供高效的数字健康解决方案。”

Value-based cancer care platform Thyme Care garnered $60 million in Series B financing, bringing its total raise to over $80 million.

基于价值的癌症护理平台Thyme care在B系列融资中获得了6000万美元，使其总筹资额达到8000多万美元。

Town Hall Ventures and Foresite Capital co-led the round with participation from existing investors Andreessen Horowitz Bio + Health, Casdin Capital, Frist Cressey Ventures and AlleyCorp.

市政厅风险投资公司和Foresite Capital共同领导了这一轮投资，现有投资者包括Andreessen Horowitz Bio+Health、Casdin Capital、Frist Cressey Ventures和AlleyCorp。

David Whelan, cofounder and general partner at Town Hall Ventures, and Elizabeth Canis, executive advisor to Foresite Capital, who previously held executive positions at Elevance and UnitedHealthcare, will join Thyme's board of directors.

市政厅风险投资公司（Town Hall Ventures）的联合创始人兼普通合伙人戴维·惠兰（David Whelan）和Foresite Capital的执行顾问伊丽莎白·卡尼斯（Elizabeth Canis）将加入百里香（Thyme）董事会。伊丽莎白·卡尼斯之前曾在Elevation和UnitedHealthcare担任高管职位。

The company will use the funds to expand its network of oncology partners and cancer care support services.

该公司将利用这些资金扩大其肿瘤学合作伙伴和癌症护理支持服务网络。

'The U.S. healthcare system is notoriously fragmented, leaving cancer patients hanging in the balance. We invest in companies that are changing the narrative by putting the patient first and are shifting the industry toward value-based care,' Whelan said in a statement.

“众所周知，美国的医疗体系支离破碎，癌症患者悬而未决。惠兰在一份声明中说，我们投资的公司正在改变叙事，将患者放在首位，并将行业转向基于价值的护理。

'Primary care and kidney care have paved the way for this transformation, and after extensively studying the landscape, we firmly believe Thyme Care is the only company with the expertise and technology to enable value-based cancer care. We look forward to helping them accelerate this mission.'

“初级保健和肾脏保健为这一转变铺平了道路，经过广泛研究，我们坚信百里香保健是唯一一家拥有专业知识和技术的公司，能够实现基于价值的癌症护理。我们期待着帮助他们加速这一使命。”

Implantable sacral neuromodulation company Neuspera Medical, Inc., closed its Series D funding round with $23 million.

植入式骶骨神经调节公司Neuspera Medical，Inc.以2300万美元结束了其D系列融资。

Vertex Ventures HC and Treo Ventures led the round with participation from Windham Venture Partners, Action Potential Venture Capital, Olympus Innovation Ventures and another strategic investor.

Vertex Ventures HC和Treo Ventures在Windham Venture Partners、Action Potential Venture Capital、Olympus Innovation Ventures和另一位战略投资者的参与下领导了这一轮。

The company makes the ultra-miniaturized Neuspera Implantable Sacral Neuromodulation System, which is designed to help patients control urinary incontinence, a symptom of an overactive bladder.

该公司生产超小型Neuspera植入式骶骨神经调节系统，旨在帮助患者控制尿失禁，这是膀胱过度活动的症状。

The Calif.-based company will use the funds to make its way through the FDA premarket approval process.

这家总部位于加利福尼亚州的公司将利用这些资金通过FDA上市前批准程序。

'As a partner of choice for innovators in urology, we are thrilled to invest in the Neuspera team as they bring the Neuspera System through FDA approval and to the market,' Gabriela Kaynor, president of Olympus Innovation Ventures and chief strategy officer at Olympus Corporation.

奥林巴斯创新创业公司总裁兼奥林巴斯公司首席战略官加布里埃尔·凯诺（GabrielaKaynor）说，作为泌尿科创新者的首选合作伙伴，我们很高兴投资Neuspera团队，因为他们通过FDA批准将Neuspera系统推向市场。

'Based on critical unmet market need and patient demand, changes in society guidelines, and positive feedback from patients and physicians in clinical trials, we are excited to invest in the Neuspera team as they build their innovative Neuspera System for OAB.'

“基于关键的未满足市场需求和患者需求，社会指南的变化以及患者和医生在临床试验中的积极反馈，我们很高兴投资Neuspera团队，因为他们为OAB构建了创新的Neuspera系统。”

The HIMSS AI in Healthcare Forum is scheduled to take place September 5-6 in Boston. Learn more and register.

HIMSS AI in Healthcare论坛定于9月5日至6日在波士顿举行。了解更多信息并注册。

Tags: Huma, Thyme Care, Neuspera

标签：

More regional news

更多地区新闻

Exclusive: Teladoc partners with Brightline to offer pediatric mental healthcareBy Jessica HagenJuly 16, 2024

独家报道：Teladoc与Brightline合作提供儿科心理健康护理Jessica Hagen2024年7月16日

HIMSS, Guidehouse partner to deploy Digital Health Indicator in MissouriBy Jessica HagenJuly 15, 2024

HIMSS，Guidehouse合作伙伴，将在密苏里州部署数字健康指标Jessica Hagen2024年7月15日

Story Health, Guidehealth partner to develop cardiology programBy Jessica HagenJuly 15, 2024

故事健康，指南健康合作伙伴开发心脏病学计划杰西卡·哈根2024年7月15日